Nomura Holdings Inc. purchased a new stake in shares of NuVasive Inc. (NASDAQ:NUVA) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 88,687 shares of the medical device company’s stock, valued at approximately $5,267,000.

Several other hedge funds have also recently added to or reduced their stakes in NUVA. Louisiana State Employees Retirement System increased its stake in NuVasive by 0.5% in the second quarter. Louisiana State Employees Retirement System now owns 22,100 shares of the medical device company’s stock worth $1,320,000 after buying an additional 100 shares in the last quarter. LS Investment Advisors LLC increased its stake in NuVasive by 7.8% in the second quarter. LS Investment Advisors LLC now owns 2,097 shares of the medical device company’s stock worth $125,000 after buying an additional 151 shares in the last quarter. American International Group Inc. increased its stake in NuVasive by 0.5% in the second quarter. American International Group Inc. now owns 36,927 shares of the medical device company’s stock worth $2,205,000 after buying an additional 179 shares in the last quarter. PineBridge Investments L.P. increased its stake in NuVasive by 4.1% in the second quarter. PineBridge Investments L.P. now owns 6,320 shares of the medical device company’s stock worth $378,000 after buying an additional 249 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in NuVasive by 1.6% in the second quarter. Arizona State Retirement System now owns 25,915 shares of the medical device company’s stock worth $1,548,000 after buying an additional 400 shares in the last quarter.

Shares of NuVasive Inc. (NASDAQ:NUVA) opened at 66.06 on Monday. The company has a 50 day moving average price of $63.84 and a 200 day moving average price of $55.92. The company has a market capitalization of $3.32 billion, a PE ratio of 68.53 and a beta of 0.86. NuVasive Inc. has a 52 week low of $36.81 and a 52 week high of $68.55.

NuVasive (NASDAQ:NUVA) last posted its earnings results on Tuesday, July 26th. The medical device company reported $0.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.04. NuVasive had a net margin of 5.28% and a return on equity of 10.57%. The company had revenue of $236.50 million for the quarter, compared to analyst estimates of $232.86 million. During the same quarter in the prior year, the business posted $0.31 EPS. The firm’s revenue was up 16.4% compared to the same quarter last year. On average, equities research analysts expect that NuVasive Inc. will post $1.65 earnings per share for the current year.

A number of analysts recently issued reports on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $70.00 target price on shares of NuVasive in a research report on Thursday, September 1st. Jefferies Group reaffirmed a “buy” rating on shares of NuVasive in a research report on Wednesday, August 3rd. Zacks Investment Research raised NuVasive from a “hold” rating to a “strong-buy” rating and set a $70.00 target price on the stock in a research report on Thursday, July 28th. TheStreet raised NuVasive from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 26th. Finally, Barclays PLC lifted their target price on NuVasive from $63.00 to $71.00 and gave the company an “overweight” rating in a research report on Wednesday, July 27th. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. NuVasive presently has an average rating of “Buy” and an average target price of $65.31.

In other NuVasive news, Director Lesley H. Howe sold 3,602 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $62.44, for a total value of $224,908.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jason Hannon sold 2,625 shares of the stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $64.80, for a total transaction of $170,100.00. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.

NuVasive Company Profile

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

5 Day Chart for NASDAQ:NUVA

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive Inc. (NASDAQ:NUVA).

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.